

Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study

Allison Barraclough,^{1,2} Shivam Agrawal,^{1,3} Dipti Talaulikar,^{4,5} Geoffrey Chong,^{1,6} Edward Yoo,^{2,7} Chan Y. Cheah,^{7,8} Nunzio Franco,^{4,5} Bianca Nguyen,² Howard Mutsando,^{9,10} Fatima Tahir,¹¹ Judith Trotman,¹¹ Jing Huang,¹² Colm Keane,¹³ Mitchel Lincoln,¹⁴ Tara Cochrane,^{15,16} Anna M. Johnston,¹⁷ Michael Dickinson,¹⁸ Stephen Opat,^{12,19} Zoe K. McQuilten,^{12,19} Erica M. Wood,^{12,19} Gayathri St George¹⁹ and Eliza A. Hawkes^{1,19}

¹Olivia Newton John Cancer Research & Wellness Center, Austin Health, Melbourne, Victoria;

²Fiona Stanley Hospital, Murdoch, Western Australia; ³Prince of Wales Hospital, Sydney, New South Wales; ⁴Canberra Health Services, Canberra, Australian Capital Territory; ⁵College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory;

⁶Ballarat Regional Integrated Cancer Center, Ballarat Health Services, Ballarat, Victoria; ⁷Sir Charles Gairdner Hospital, Nedlands, Western Australia; ⁸Medical School, University of Western Australia, Perth, Western Australia; ⁹Toowoomba Hospital, Toowoomba,

Queensland; ¹⁰University of Queensland Rural Clinical School, Brisbane, Queensland;

¹¹Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; ¹²School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria;

¹³Princess Alexandra Hospital, Brisbane, Queensland; ¹⁴Alfred Hospital, Melbourne, Victoria;

¹⁵Gold Coast University Hospital, Southport, Queensland; ¹⁶School of Medicine, Griffith University, Griffith, Queensland; ¹⁷Royal Hobart Hospital, Hobart, Tasmania; ¹⁸Peter

MacCallum Cancer Center and The Royal Melbourne Hospital, Melbourne, Victoria and

¹⁹School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria,

Australia

Correspondence: E. Hawkes
eliza.hawkes@onjcri.org.au

Received: October 25, 2023.

Accepted: February 28, 2024.

Early view: March 7, 2024.

<https://doi.org/10.3324/haematol.2023.284538>

©2024 Ferrata Storti Foundation

Published under a CC BY-NC license



Supplementary Tables

Supplementary Table S1. Modified GELF criteria by treatment group

Management	Number of mGELF criteria								Total
	0	1	2	3	4	5	6	7	
Watch & Wait	20	15	5	2	0	0	1	0	43
Systemic Therapy +/- Radiation	28	34	19	21	11	6	1	1	121
Radiation Alone	3	4	1	1	0	0	0	0	9
Total	51	53	25	24	11	6	2	1	173

Supplementary Table S1. Modified GELF criteria by treatment group

GELF Groupe d'Etude des Lymphomes Folliculaires

Supplementary Table S2. Distribution of modified GELFc by management group

MANAGEMENT STRATEGY	SPECIFIC GELF CRITERION								LDH>ULN (n=43)	B2MG>ULN (n=56)
	Mass >7cms (n=47)	≥ 3 sites each >3cm diameter (n=30)	B Symptoms (n=29)	Splenomegaly (n=19)	Compression (n=22)	Effusion (n=12)	Leukaemic phase (n=7)	Cytopenias (n=3)		
Watch & Wait (%)	3 (6)	4 (13)	7 (24)	1 (5)	1 (5)	1 (8)	1 (14)	1 (33)	8 (19)	10 (18)
Systemic Therapy +/- RT (%)	43 (92)	26 (87)	18 (62)	17 (89)	20 (90)	11 (92)	6 (86)	2 (67)	34 (79)	45 (80)
Radiotherapy Alone (%)	1 (2)	0 (0)	4 (14)	1 (5)	1 (5)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)

Supplementary Table S2. Distribution of modified GELFc by management group

GELFc=Groupe d'Etude des Lymphomes Folliculaires criteria, n=number, cm=centimetres, RT=Radiotherapy, LDH=lactate dehydrogenase, ULN=upper limit of normal